Neuropathix, Inc. (OTCQB: NPTX) is a biopharmaceutical company focused on the research and development of a pipeline of next generation socially responsible pain management and neuroprotective therapeutics to treat patients with significant unmet medical needs. Over the past ten years, Neuropathix has discovered, developed and patented a global intellectual property estate, led by its lead clinical target, KLS-13019, as novel new therapeutic agents designed to prevent and reverse neuropathic pain, reduce oxidative stress, and act as anti-inflammatory neuroprotectants.
The Company’s family of patented monotherapeutic molecules focuses on treating oxidative stress-related diseases, chronic pain management and neurodegenerative disorders. The therapeutic targets include chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury (mTBI), a disorder associated with single and repetitive impact injuries; and chronic traumatic encephalopathy (CTE), a disease associated with highly repetitive impact injuries in professional and amateur sports. Neuropathix conducts its research and development efforts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA.
For more information, visit the Company’s website at www.neuropathix.com
To watch the presentation, visit https://ibn.fm/NeuropathixPresentation
To view IBN’s virtual coverage of the LD Micro Main Event, visit https://ibn.fm/LDMicroXIII
About InvestorBrandNetwork’s Virtual Coverage
The InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company, is providing the online investment community with a custom-built portal that includes summaries on each of the publicly traded companies participating virtually at the LD Micro Main Event. In addition to enabling proficient evaluation of each company via one-click access to market research tools and helpful website links, IBN is using social media and syndicated articles to maximize the visibility of the LD Micro Main Event.
For more than a decade, IBN has provided real-time coverage for numerous global events and conferences through its various brands, social media accounts and investment newsletters. To further expand visibility of participating companies at these events, and to ensure another successful year for its event collaborations in 2020, IBN’s syndication partners have extended digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]
Neuropathix Contacts:
Public Relations:
Kathryn Brown
Account Supervisor
CMW Media
P. 858-264-6600
E: [email protected]
www.cmwmedia.com
Investor Relations:
Louie Toma
Managing Director
CORE IR
P: 516-222-2560
E: [email protected]
www.coreir.com